Finch Therapeutics Group (FNCH) Set to Announce Quarterly Earnings on Monday

Finch Therapeutics Group (NASDAQ:FNCH – Get Rating) is scheduled to post its quarterly earnings results before the market opens on Monday, May 16th.

NASDAQ FNCH opened at $2.15 on Tuesday. The stock has a 50-day moving average price of $4.49. Finch Therapeutics Group has a 52 week low of $2.02 and a 52 week high of $22.10. The company has a market cap of $102.20 million, a PE ratio of -1.11 and a beta of 0.89.

Several large investors have recently modified their holdings of FNCH. BlackRock Inc. raised its holdings in Finch Therapeutics Group by 2.2% during the fourth quarter. BlackRock Inc. now owns 395,782 shares of the company’s stock worth $3,946,000 after purchasing an additional 8,443 shares in the last quarter. Millennium Management LLC bought a new stake in shares of Finch Therapeutics Group in the 4th quarter worth $126,000. D. E. Shaw & Co. Inc. acquired a new stake in shares of Finch Therapeutics Group in the fourth quarter valued at $274,000. Citadel Advisors LLC bought a new position in Finch Therapeutics Group during the fourth quarter valued at about $771,000. Finally, State Street Corp grew its holdings in Finch Therapeutics Group by 1.7% during the fourth quarter. State Street Corp now owns 106,219 shares of the company’s stock worth $1,059,000 after acquiring an additional 1,807 shares during the period. 22.68% of the stock is owned by institutional investors.

FNCH has been the subject of a number of recent analyst reports. Jefferies Financial Group decreased their price objective on Finch Therapeutics Group from $29.00 to $17.00 and set a “buy” rating for the company in a report on Monday, April 4th. Zacks Investment Research raised Finch Therapeutics Group from a “hold” rating to a “buy” rating and set a $5.75 price target on the stock in a report on Tuesday, April 5th.

Finch Therapeutics Group Company Profile (Get Rating)

Finch Therapeutics Group, Inc, a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that is in Phase 3 clinical trial for the treatment of patients with recurrent Clostridioides difficile infection, as well as for the treatment of chronic hepatitis B virus.

Further Reading